Symptom relief and not cyst reduction determines treatment success in aspiration sclerotherapy of hepatic cysts.

ABSTRACT:

Objective

To assess whether quantitative assessment of symptom reduction is a better outcome parameter than cyst volume reduction for treatment success in patients treated by aspiration sclerotherapy.

Methods

We included patients with symptomatic, large (> 5 cm), hepatic cysts from a randomized controlled trial (NCT02048319). At baseline and 6 months after treatment, symptoms were assessed with the polycystic liver disease questionnaire (PLD-Q) and we measured cyst volume using ultrasonography. Patient-reported change in health was assessed on a 5-point Likert scale (much worse to much better) after 6 months. We tested whether PLD-Q scores and cyst volumes changed after aspiration sclerotherapy (responsiveness). Changes in PLD-Q scores and cyst volume were compared with chan

SUBMITTER: Neijenhuis MK 

PROVIDER: S-EPMC6510865 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature